ImmunoGen: Corporate Presentation (Immunogen) - May 2, 2015 - “STARLYTE Ph 2 trial, Single agent for previously treated DLBCL”; “Proof-of-concept achieved per study investigators, 43.9% ORR vs. 20% pre-set threshold (per protocol population); “Efficacy demonstrated in hard-to-treat DLBCL patient populations, Relapsed (n=26): 53.8% ORR, with 5 CRs, 9 PRs, Refractory to last treatment (n=15): 26.7% ORR, with 1 CR, 3 PRs, Primary refractory (n=14): 21.4% ORR, with 1 CR, 2 PRs”; “Favorable tolerability profile, few grade 3/4 adverse events, Any ocular events were grade 1/2, reversible and manageable”
P2 data • Non-Hodgkin's Lymphoma • Oncology
|